HUS2500017I1 - Szöveti faktor bioszintézis út elleni ellenanyagok - Google Patents

Szöveti faktor bioszintézis út elleni ellenanyagok

Info

Publication number: HUS2500017I1
Authority: HU; Hungary
Prior art keywords: antibodies against; tissue factor; pathway inhibitor; against tissue; factor pathway
Prior art date: 2008-12-22

Application number

HUS2500017C

Other languages

English (en)

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2025-03-25

Publication date

2025-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2500017(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2025-03-25 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2025-04-28 Publication of HUS2500017I1 publication Critical patent/HUS2500017I1/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUS2500017C 2008-12-22 2025-03-25 Szöveti faktor bioszintézis út elleni ellenanyagok HUS2500017I1 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08172520		2008-12-22
EP09793543.1A EP2379600B2 (en)	2008-12-22	2009-12-18	Antibodies against tissue factor pathway inhibitor

Publications (1)

Publication Number	Publication Date
HUS2500017I1 true HUS2500017I1 (hu)	2025-04-28

Family

ID=40639722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUS2500017C HUS2500017I1 (hu)	2008-12-22	2025-03-25	Szöveti faktor bioszintézis út elleni ellenanyagok

Country Status (23)

Country	Link
US (5)	US8361469B2 (hu)
EP (3)	EP2746294A3 (hu)
JP (2)	JP5714505B2 (hu)
KR (2)	KR101745394B1 (hu)
CN (1)	CN102325795B (hu)
AU (1)	AU2009331570C1 (hu)
BR (1)	BRPI0924058B1 (hu)
CA (1)	CA2745317C (hu)
DK (1)	DK2379600T4 (hu)
ES (1)	ES2458665T5 (hu)
FI (1)	FIC20250014I1 (hu)
FR (2)	FR24C1008I1 (hu)
HU (1)	HUS2500017I1 (hu)
IL (1)	IL213356A (hu)
MX (1)	MX2011006501A (hu)
NL (1)	NL301310I2 (hu)
NO (1)	NO2025013I1 (hu)
PL (1)	PL2379600T5 (hu)
PT (1)	PT2379600E (hu)
RU (1)	RU2562114C2 (hu)
TW (1)	TWI476003B (hu)
WO (1)	WO2010072691A1 (hu)
ZA (1)	ZA201104599B (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20110039218A (ko)	2008-06-30	2011-04-15	노보 노르디스크 에이/에스	항－인간 인터루킨－２０ 항체
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
PT2379600E (pt) *	2008-12-22	2014-04-29	Novo Nordisk As	Anticorpos contra inibidor da via de fator tecidual
US8454956B2 (en)	2009-08-31	2013-06-04	National Cheng Kung University	Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
SI3409289T1 (sl) *	2010-02-26	2020-12-31	Novo Nordisk A/S	Stabilni sestavki, ki vsebujejo protitelo
PL2542257T3 (pl)	2010-03-01	2018-01-31	Bayer Healthcare Llc	Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
AU2011257219B2 (en) *	2010-05-28	2014-12-04	Novo Nordisk A/S	Stable multi-dose compositions comprising an antibody and a preservative
JP2013533871A (ja) *	2010-06-30	2013-08-29	ノヴォノルディスクアー／エス	組織因子経路インヒビターに特異的に結合することが可能な抗体
US9228022B2 (en)	2010-06-30	2016-01-05	Novo Nordisk A/S	Antibodies that are capable of specifically binding tissue factor pathway inhibitor
WO2012135671A2 (en) *	2011-04-01	2012-10-04	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2014015133A1 (en)	2012-07-19	2014-01-23	National Cheng Kung University	Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en)	2012-08-07	2014-10-07	National Cheng Kung University	Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
CN105209496A (zh) *	2013-03-15	2015-12-30	拜尔健康护理有限责任公司	针对组织因子途径抑制剂的前体药物抗体
EP2970497B1 (en)	2013-03-15	2017-10-25	Bayer HealthCare LLC	Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
WO2014140240A1 (en)	2013-03-15	2014-09-18	Novo Nordisk A/S	Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
JP6584397B2 (ja) *	2013-07-19	2019-10-02	ノヴォノルディスクアー／エス	凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
CA2921652A1 (en)	2013-08-21	2015-02-26	Manuel A. Riquelme	Compositions and methods for targeting connexin hemichannels
SG10201804945WA (en) *	2013-12-12	2018-07-30	Shanghai hengrui pharmaceutical co ltd	Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN106573977B (zh) *	2014-04-27	2020-08-07	菲姆威有限公司	针对ceacam1的人源化抗体
EP3194447B1 (en) *	2014-09-17	2021-12-01	Novo Nordisk A/S	Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX388251B (es) *	2015-02-25	2025-03-19	Mogam Inst Biomedical Res	Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
KR102438650B1 (ko) *	2015-08-19	2022-08-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
US10889637B2 (en)	2016-02-26	2021-01-12	The Board Of Regents Of The University Of Texas System	Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
TWI788321B (zh)	2017-01-20	2023-01-01	美商健臻公司	骨靶向抗體
TWI856437B (zh)	2017-01-20	2024-09-21	法商賽諾菲公司	抗TGF-β抗體及其用途
JP7094722B2 (ja) *	2018-02-28	2022-07-04	キヤノン株式会社	画像読取装置及び画像形成装置
KR102337683B1 (ko)	2018-09-21	2021-12-13	주식회사 녹십자	고효율 항-tfpi 항체 조성물
US20210395391A1 (en) *	2018-10-11	2021-12-23	Pfizer Inc.	Dosage Regimen for TFPI Antagonists
JP7774293B2 (ja) *	2019-07-24	2025-11-21	国立研究開発法人科学技術振興機構	抗体酵素の革新的製造技術
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体
MX2022005836A (es) *	2019-11-13	2022-06-09	Pfizer	Formulacion estable de anticuerpos acuosos.
MX2022015959A (es) *	2020-07-02	2023-01-24	Beijing Tuo Jie Biopharmaceutical Co Ltd	Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
JP7278503B2 (ja) *	2020-09-24	2023-05-19	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	コンシズマブの医薬製剤およびその生産方法
CN116136537A (zh) *	2021-11-16	2023-05-19	北京积水潭医院	组织因子途径抑制物抗凝活性的检测方法和试剂盒及其应用
CN118613492A (zh) *	2022-01-30	2024-09-06	西湖大学	Tfpi结合多肽及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966852A (en) †	1987-07-23	1990-10-30	Monsanto Company	DNA clone of human tissue factor inhibitor
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
DK261490D0 (da)	1990-10-31	1990-10-31	Novo Nordisk As	New pharmaceutical compound
EP0539975A1 (en) †	1991-10-31	1993-05-05	Teijin Limited	Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
JPH06153981A (ja)	1992-11-30	1994-06-03	Teijin Ltd	Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) *	1993-11-05	1995-10-03	Zymogenetics, Inc.	DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en)	1994-08-05	1996-12-31	Chiron Corporation	Chimeric proteins
JPH0875736A (ja)	1994-09-06	1996-03-22	Chemo Sero Therapeut Res Inst	ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) *	1995-09-05	1999-05-11	Chiron Corporation	Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja)	1995-12-26	2005-08-10	株式会社三菱化学ヤトロン	抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
JP2002505574A (ja)	1997-04-30	2002-02-19	エンゾン，インコーポレイテッド	ポリアルキレンオキシド修飾された単鎖ポリペプチド
AU785038B2 (en) *	2000-01-27	2006-08-31	Applied Molecular Evolution, Inc.	Ultra high affinity neutralizing antibodies
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja)	2003-10-28	2007-11-29	ノボ　ノルディスク　アクティーゼルスカブ	ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US7585842B2 (en)	2004-04-16	2009-09-08	The Reagents Of The University Of California	Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) *	2004-05-06	2006-03-21	National Semiconductor Corporation	Bootstrapped bias mixer with soft start POR
DE602006021290D1 (de) †	2005-03-04	2011-05-26	Univ Illinois	Modulator von coagulationskaskaden und fibrinolytischen kaskaden
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379096B1 (en) *	2008-12-19	2019-10-30	Baxalta GmbH	Tfpi inhibitors and methods of use
CN102300876A (zh) *	2008-12-22	2011-12-28	诺沃—诺迪斯克有限公司	针对组织因子途径抑制剂(tfpi)的抗体
PT2379600E (pt) *	2008-12-22	2014-04-29	Novo Nordisk As	Anticorpos contra inibidor da via de fator tecidual
US8965454B2 (en)	2009-03-04	2015-02-24	Andrew Llc	Amplifier system for cell sites and other suitable applications
US8598327B2 (en)	2009-08-18	2013-12-03	Baxter International Inc.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
MX2012002133A (es)	2009-08-18	2013-02-15	Baxter Healthcare Sa	Aptameros para inhibidor de trayectoria de factor de tejido y su uso como terapeuticos para trastorno de sangrado.
PL2542257T3 (pl) †	2010-03-01	2018-01-31	Bayer Healthcare Llc	Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
US8598008B2 (en) †	2010-10-20	2013-12-03	Texas Instruments Incorporated	Stacked ESD clamp with reduced variation in clamp voltage
AU2012214148A1 (en) †	2011-02-11	2013-08-29	Baxter Healthcare S.A.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2012135671A2 (en) †	2011-04-01	2012-10-04	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2827910A2 (en) †	2012-03-22	2015-01-28	Baxter International Inc	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2014140240A1 (en)	2013-03-15	2014-09-18	Novo Nordisk A/S	Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
MX388251B (es) †	2015-02-25	2025-03-19	Mogam Inst Biomedical Res	Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
KR102438650B1 (ko) †	2015-08-19	2022-08-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도

2009
- 2009-12-18 PT PT97935431T patent/PT2379600E/pt unknown
- 2009-12-18 ES ES09793543T patent/ES2458665T5/es active Active
- 2009-12-18 MX MX2011006501A patent/MX2011006501A/es active IP Right Grant
- 2009-12-18 EP EP14151704.5A patent/EP2746294A3/en not_active Withdrawn
- 2009-12-18 RU RU2011129068/10A patent/RU2562114C2/ru active
- 2009-12-18 WO PCT/EP2009/067598 patent/WO2010072691A1/en not_active Ceased
- 2009-12-18 AU AU2009331570A patent/AU2009331570C1/en active Active
- 2009-12-18 BR BRPI0924058-6A patent/BRPI0924058B1/pt active IP Right Grant
- 2009-12-18 EP EP09793543.1A patent/EP2379600B2/en active Active
- 2009-12-18 PL PL09793543T patent/PL2379600T5/pl unknown
- 2009-12-18 CA CA2745317A patent/CA2745317C/en active Active
- 2009-12-18 US US13/140,296 patent/US8361469B2/en active Active
- 2009-12-18 KR KR1020167005204A patent/KR101745394B1/ko active Active
- 2009-12-18 DK DK09793543.1T patent/DK2379600T4/da active
- 2009-12-18 EP EP17176891.4A patent/EP3260466A1/en not_active Withdrawn
- 2009-12-18 KR KR1020117016958A patent/KR101600308B1/ko active Active
- 2009-12-18 CN CN200980157157.2A patent/CN102325795B/zh active Active
- 2009-12-18 JP JP2011541494A patent/JP5714505B2/ja active Active
- 2009-12-22 TW TW098144133A patent/TWI476003B/zh active
2011
- 2011-06-05 IL IL213356A patent/IL213356A/en active IP Right Grant
- 2011-06-22 ZA ZA2011/04599A patent/ZA201104599B/en unknown
2012
- 2012-12-20 US US13/721,802 patent/US8652471B2/en active Active
- 2012-12-20 US US13/721,755 patent/US9574011B2/en active Active
2015
- 2015-03-11 JP JP2015048157A patent/JP6114326B2/ja active Active
2017
- 2017-01-06 US US15/400,366 patent/US20170114147A1/en not_active Abandoned
2019
- 2019-03-25 US US16/363,327 patent/US20190211112A1/en not_active Abandoned
2024
- 2024-02-26 FR FR24C1008C patent/FR24C1008I1/fr active Active
- 2024-12-20 NL NL301310C patent/NL301310I2/nl unknown
2025
- 2025-02-25 NO NO2025013C patent/NO2025013I1/no unknown
- 2025-03-17 FI FIC20250014C patent/FIC20250014I1/fi unknown
- 2025-03-25 HU HUS2500017C patent/HUS2500017I1/hu unknown
- 2025-04-10 FR FR25C1014C patent/FR25C1014I1/fr active Active

Also Published As

Publication number	Publication date
CN102325795B (zh)	2015-03-25
WO2010072691A1 (en)	2010-07-01
RU2562114C2 (ru)	2015-09-10
US20110318356A1 (en)	2011-12-29
US20130251721A1 (en)	2013-09-26
JP6114326B2 (ja)	2017-04-12
AU2009331570C1 (en)	2024-04-18
IL213356A (en)	2017-06-29
EP2379600A1 (en)	2011-10-26
AU2009331570B2 (en)	2013-10-17
EP2379600B1 (en)	2014-01-22
NL301310I2 (nl)	2025-02-11
FR24C1008I1 (fr)	2024-04-19
TW201026330A (en)	2010-07-16
FR25C1014I1 (fr)	2025-06-20
MX2011006501A (es)	2011-07-12
US20130251722A1 (en)	2013-09-26
US8652471B2 (en)	2014-02-18
BRPI0924058A2 (pt)	2019-10-15
DK2379600T4 (da)	2021-01-04
KR20160031028A (ko)	2016-03-21
CA2745317C (en)	2019-03-05
EP2746294A2 (en)	2014-06-25
DK2379600T3 (da)	2014-04-28
ES2458665T9 (en)	2025-04-22
ES2458665T3 (es)	2014-05-06
KR101745394B1 (ko)	2017-06-09
AU2009331570A1 (en)	2011-06-30
US8361469B2 (en)	2013-01-29
CA2745317A1 (en)	2010-07-01
KR20110103432A (ko)	2011-09-20
EP2379600B2 (en)	2020-10-14
TWI476003B (zh)	2015-03-11
ZA201104599B (en)	2012-03-28
PT2379600E (pt)	2014-04-29
CN102325795A (zh)	2012-01-18
KR101600308B1 (ko)	2016-03-07
IL213356A0 (en)	2011-07-31
RU2011129068A (ru)	2013-01-27
FIC20250014I1 (fi)	2025-03-17
BRPI0924058B1 (pt)	2021-08-17
PL2379600T5 (pl)	2021-03-08
ES2458665T5 (es)	2021-06-30
EP2746294A3 (en)	2015-01-07
US9574011B2 (en)	2017-02-21
NO2025013I1 (no)	2025-02-25
US20190211112A1 (en)	2019-07-11
PL2379600T3 (pl)	2014-07-31
JP2012513377A (ja)	2012-06-14
JP5714505B2 (ja)	2015-05-07
US20170114147A1 (en)	2017-04-27
EP3260466A1 (en)	2017-12-27
JP2015178495A (ja)	2015-10-08

Publication	Publication Date	Title
HUS2500017I1 (hu)	2025-04-28	Szöveti faktor bioszintézis út elleni ellenanyagok
IL282658A (en)	2021-06-30	Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
PL2949666T3 (pl)	2019-07-31	Ludzkie przeciwciała przeciwko alfa-synukleinie
ZA201100898B (en)	2012-02-29	Novel inhibitors
GB0820117D0 (en)	2008-12-10	Tourniquet
ZA201102837B (en)	2011-12-28	Phosphodiestarase inhibitors
GB0714941D0 (en)	2007-09-12	Inhibitors
HRP20190159T1 (hr)	2019-03-22	Antitijela humanog anti-alfa-sinukleina
GB201019387D0 (en)	2010-12-29	Inhibitors
GB0809820D0 (en)	2008-07-09	Modified tissues
GB0713152D0 (en)	2007-08-15	Phosphodlesterase inhibitors
GB0816125D0 (en)	2008-10-15	Novel inhibitors
GB0720364D0 (en)	2007-11-28	Inhibitor
PH32008000854S1 (en)	2009-02-16	Tissue
GB0804978D0 (en)	2008-04-16	Reflection
GB0707488D0 (en)	2007-05-23	Novel inhibitors
GB0704589D0 (en)	2007-04-18	Novel inhibitors
GB0707499D0 (en)	2007-05-23	Novel inhibitors
GB0707632D0 (en)	2007-05-30	Novel inhibitors
GB0707493D0 (en)	2007-05-23	Novel inhibitors
GB0707498D0 (en)	2007-05-23	Novel inhibitors
GB0707495D0 (en)	2007-05-23	Novel inhibitors
GB0707497D0 (en)	2007-05-23	Novel inhibitors
GB0803891D0 (en)	2008-04-09	Glyoxalase inhibitors
GB0803994D0 (en)	2008-04-09	Pipeline